A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer

ClinicalTrials.gov ID: NCT02725268

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02725268. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study is to determine if sapanisertib in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.

Study identification

NCT ID: NCT02725268
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Enrollment: 241 participants

Conditions and interventions

Conditions

Endometrial Neoplasms

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 1, 2016 (Actual)
Primary completion: Jul 2, 2019 (Actual)
Completion: Oct 30, 2020 (Actual)
Last update posted: Nov 24, 2021

2016 – 2020

United States locations

U.S. sites: 21
U.S. states: 15
U.S. cities: 20

Facility	City	State	ZIP	Site status
University of Alabama Comprehensive Cancer Center	Birmingham	Alabama	35294-3300	—
University of Arizona Cancer Center	Phoenix	Arizona	85013	—
Marin Cancer Care	Greenbrae	California	94904	—
University of California San Diego Medical Center	La Jolla	California	92093-1503	—
University of California at San Francisco (PARENT)	San Francisco	California	94115	—
Stanford School of Medicine	Stanford	California	94305	—
H. Lee Moffitt Cancer Center and Research Institute, Inc	Tampa	Florida	33612-9416	—
Florida Cancer Specialists	West Palm Beach	Florida	33401	—
Augusta University	Augusta	Georgia	30912	—
Franciscan St. Francis Health	Indianapolis	Indiana	46237	—
University of Kansas Medical Center Research Institute, Inc.	Westwood	Kansas	66205	—
Massachusetts General Hospital Cancer Center	Boston	Massachusetts	02114	—
Washington University	St Louis	Missouri	63108	—
NYU Langone Medical Center Clinic	New York	New York	10016	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065-6094	—
Levine Cancer Institute	Charlotte	North Carolina	28204	—
Oklahoma University Health Sciences Center	Oklahoma City	Oklahoma	73104	—
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	—
University of Pittsburgh Medical Center Cancer Center at Magee-Womens Hospital	Pittsburgh	Pennsylvania	15232	—
Sarah Cannon Research Institute	Nashville	Tennessee	37203	—
University of Texas Southwestern Medical Center	Dallas	Texas	75390	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02725268, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 24, 2021 · Synced Nov 14, 2026